China's BeiGene prices $200m follow-on

GLOBALCAPITAL INTERNATIONAL LIMITED, a company

incorporated in England and Wales (company number 15236213),

having its registered office at 4 Bouverie Street, London, UK, EC4Y 8AX

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Asia

China's BeiGene prices $200m follow-on

Jonathan Breen
November 18, 2016 07:00 AM
capsule px230

Chinese biopharmaceutical company BeiGene has net $200m from a follow-on public offering of American Depositary Shares (ADSs).

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

EquityChinaAmericasAsia Follow-ons and Rights IssuesGreater ChinaAsiaMorgan StanleyNortheast AsiaAsia PacificUnited StatesFollow-ons and Rights issuesEmerging MarketsNorth AmericaGoldman Sachs
JB
Jonathan Breen
Equities editor GlobalCapital Asia
Contact
Gift this article